Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. (2021)

First Author: Langley RE
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)00100-8

PubMed Identifier: 33581820

Publication URI: http://europepmc.org/abstract/MED/33581820

Type: Journal Article/Review

Volume: 397

Parent Publication: Lancet (London, England)

Issue: 10274

ISSN: 0140-6736